India’s drug pricing authority has given Abbott (NYSE:ABT) a year to pull its Xience Alpine drug-eluting stent from the market, according to an Indian Economic Times report.
The company approached India’s National Pharmaceutical Pricing Authority nearly a month ago looking to withdraw the device, citing price caps set on stents earlier this year.
Get the full story at our sister site, Drug Delivery Business News.
